Neil Buckley

Geschäftsführer bei Lusaris Therapeutics, Inc.

Health Technology

Aktive Beziehungen

Name	Geschlecht	Alter	Unternehmensverbindungen	Zusammenarbeit
Andrew Levin	M	47	Lusaris Therapeutics, Inc. Lusaris Therapeutics, Inc. BiotechnologyHealth Technology Lusaris Therapeutics, Inc. is a biotechnology company that focuses on developing next-generation serotonergic neuroplastogen therapeutics to treat severe neuropsychiatric and neurological disorders. The company is based in Boston, MA. The company's lead program, LSR-1019, is a proprietary sublingual formulation of 5-MeO-DMT, a rapidly acting and rapidly clearing serotonergic psychedelic, which is being developed to treat treatment-resistant depression and other neuropsychiatric conditions. The company's pipeline also includes novel neuroplastogens for a wide range of neuropsychiatric and neurological conditions, including migraine and cluster headache. The CEO of the company is Andrew D. Levin.	-
Edward P. Monaghan	M	-	Lusaris Therapeutics, Inc. Lusaris Therapeutics, Inc. BiotechnologyHealth Technology Lusaris Therapeutics, Inc. is a biotechnology company that focuses on developing next-generation serotonergic neuroplastogen therapeutics to treat severe neuropsychiatric and neurological disorders. The company is based in Boston, MA. The company's lead program, LSR-1019, is a proprietary sublingual formulation of 5-MeO-DMT, a rapidly acting and rapidly clearing serotonergic psychedelic, which is being developed to treat treatment-resistant depression and other neuropsychiatric conditions. The company's pipeline also includes novel neuroplastogens for a wide range of neuropsychiatric and neurological conditions, including migraine and cluster headache. The CEO of the company is Andrew D. Levin.	-
Daniel S. Grau	M	57	Lusaris Therapeutics, Inc. Lusaris Therapeutics, Inc. BiotechnologyHealth Technology Lusaris Therapeutics, Inc. is a biotechnology company that focuses on developing next-generation serotonergic neuroplastogen therapeutics to treat severe neuropsychiatric and neurological disorders. The company is based in Boston, MA. The company's lead program, LSR-1019, is a proprietary sublingual formulation of 5-MeO-DMT, a rapidly acting and rapidly clearing serotonergic psychedelic, which is being developed to treat treatment-resistant depression and other neuropsychiatric conditions. The company's pipeline also includes novel neuroplastogens for a wide range of neuropsychiatric and neurological conditions, including migraine and cluster headache. The CEO of the company is Andrew D. Levin.	-